43
1 Pharmacyclics Corporate Presentation March 2014
1PharmacyclicsCorporate Presentation
March 2014
2During the course of this presentation we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the FDA, the status and timing of ongoing research, corporate partnering activities and other factors affecting Pharmacyclics financial condition or operations. Such forward-looking statements are not guarantees of future performance and involve risks, uncertainties and other factors that may cause actual results, performance or achievements to vary materially from those expressed or implied in such statements. These and other risk factors are listed from time to time in reports filed with the Securities and Exchange Commission (SEC), including but not limited to, reports on Forms 10-Q and 10-K. Pharmacyclics does not intend to update any forward-looking information to reflect actual results or changes in the factors affecting the forward-looking information.
Safe Harbor Statement
3Making a difference for the betterment of patients
Our MissionTo build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious medical healthcare needs.To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and to pursue commercialization and/or development partners when and where appropriate.We exist to make a difference for the better and these are important times to do just that.
4PCYC Corporate Development Jan 2006 to Dec 2008
$0
$1
$2
$3
$4
$5
$6
SharePrice
$0.79
$5.07$4.92
$1.45
04/10/06:AssumptionofCeleracompoundsBTK,FVIIa,HDAC
09/11/08:PCYC Board&ManagementTransition
09/19/07:BobDugganjoinsPCYCBoard 05/01/08:
Offertopurchase4M sharesat$1.05/sharebyRWDuggan
10/21/07:FDA NonapprovableletterforXcytrin
02/22/07:FDARefusaltofile letterforXcytrin
5PCYC Corporate DevelopmentJan 2009 to Mar 2014
$0
$20
$40
$60
$80
$100
$120
$140
$160
SharePrice
02/12/14:IMBRUVICAapproved forCLLptsw/atleastonepriortherapy.
$57.78
$3.14$6.08
$14.828/5/2009RightsOffering22.5Msharessoldat$1.28
07/17/11:SecondaryOffering6.5Msharessoldat$8.85
11/13/13:IMBRUVICAapproved forMCLptsw/atleastonepriortherapy.PCYC'sfirstlabel.
12/31/08Price: $0.79Employees:47Mkt Cap:$20MW.Cap: $7.2M$6MloanbyR.W.Duggan
07/10/13: PCYCannounceditsfirstNDAfilingofibrutinib,fortreatmentofpatientswithR/RCLLandR/RMCL.
2/12/13: PCYCreceivesBreakthroughTherapyDesignationfromtheFDAforMCLandWM. $70.37
12/8/11: PCYCentersintocollaborationagreementwithJanssenBiotech,Inc.
6/21/10: PCYCraises$50.8Mnetproceedsinaregistereddirectoffering.$6.74
6IMBRUVICA Approved November 13, 2013 in MCL and February 12, 2014 in CLL
4.5yearsfrom1st patientintoNDAfiling 4.5monthsfromfilingtofirstFDAapproval
7[IMBRUVICA]isarevolutionarybloodcancerdrug.
Headlines and Highlights.Approval Grabs Attention of Top Tier Media
FDA speedily approves Imbruvica, a treatment
for rare lymphoma
J&J-Pharmacyclics Win U.S. Approval for
Breakthrough Drug
8IMBRUVICA (ibrutinib)Leads Our Oncology Pipeline
Molecule & Program / Indication Discovery / Preclinical
Phase I
Phase II
Phase III
Ibrutinib (PCI-32765): Brutons tyrosine kinase (BTK) inhibitor for Oncology *
Chronic lymphocytic leukemia
Mantle cell lymphoma
Diffuse large B-cell lymphoma
Multiple myeloma
Follicular lymphoma
Waldenstroms Macroglobulinemia
Abexinostat HCI (PCI-24781): Histone deacetylase (HDAC) inhibitor for Oncology **
Follicular lymphoma and mantle cell lymphoma
PCI-27483: Factor VIIa Inhibitor for Oncology
Pancreatic cancer
BTK inhibitor for Autoimmune Diseases
Autoimmune disease*Janssen Biotech: global partnership ** Servier: ex-U.S. partnership
APPROVEDAPPROVED
9IMBRUVICA (Ibrutinib - PCI-32765)
IMBRUVICA is an oral therapy that targets an importantpathway in B-cell malignancies. Over 2800 patientstreated in company sponsored clinical trials.
IMBRUVICA was approved for the treatment ofpatients with mantle cell lymphoma who have received at least one prior therapy
IMBRUVICA has demonstrated in clinical trials:o Tumor reduction (response) in heavily pretreated patientso Responses in patients previously treated with
chemotherapy and with aggressive diseaseo Durable responses with many patients still on drug after
prolonged periods of timeo Patient tolerability demonstrated
10
BTK Signaling Pathway
11
From: de Rooij et al, Blood 119: 2590-2594
Mechanism of BTK: IMBRUVICA (ibrutinib PCI-32765) Blocks Malignant B-cell Growth and Proliferation
ChronicLymphocyticLeukemiaCell LymphNode PeripheralBlood
12
B-Cell Development andOrigin of B-cell Malignancies
Pre-B ImmatureBNave
BGerminalCenter B
MemoryB
PlasmaCell
Malignant:
Leukemia
Chronic Lymphocytic
Leukemia (CLL)un-mutated Mantle Cell Lymphoma
(MCL)Multiple Myeloma
(MM)
Adopted from:2012 Pan Pacific Lymphoma ConferenceJ Rubenstein, M.D., Ph.D.
Normal :
Immature antibody producing
Chronic Lymphocytic
Leukemia mutated
Follicular Lymphoma (FL)
Diffuse Large B-Cell Lymphoma (DLBCL)
WaldenstromsMacroglobulinemia (WM)
13
Clinical Program Overview
14
Patient Populations in Major Hematology Malignancies
US All Major Markets*Incidence Prevalence Incidence Prevalence
CLL/SLL 16,0001 114,5002 40,0001 259,0001
MCL 2,9001 11,3002 6,0001 37,0001
WM 1,5004 12,0002 6,0004 23,0004
DLBCL 25,0001 112,0002 53,0001 356,0001
FL 13,0001 63,0002 28,0001 240,0001
MM 20,0001 77,0001 48,0001 183,0001
TOTAL 82,500 390,0002 181,000 1,100,0001
12013DR/DecisionResources,LLC.Allrightsreserved.Reproduction,distribution,transmissionorpublicationisprohibited. Reprintedwithpermission.FortheCLLdiagnosedincidencetheUSNationalCancerInstituteestimationswereused2 IMSpatientclaimsestimatesforJuly2012June2013.Note:ThisinformationisanestimatederivedfromtheuseofinformationunderlicensefromthefollowingIMSHealthIncorporatedinformationservice:IMSOncologyTrackingReportsfortheperiodJuly2012toJune2013.IMSexpresslyreservesallrights,includingrightsofcopying,distributionandrepublication.
3 Majormarketsinclude:US,UK,Spain,Germany,France,Italy,andJapan4 WMFoundationestimatePharmacyclics,Inc.makesnorepresentationwithrespecttotheaccuracyorreliabilityofthisinformation. Investorsareadvisedtoindependentlyverifythisinformationbeforeusingittomakeinvestmentdecisions.
15
CLL/SLL & MCL US Patient Estimates
CLL/SLL MCLDiagnosed Incidence 1 16,000 2,900
Prevalence 2 114,500 11,300
No Therapy 2 50,600 2,000
1L Therapy 2 23,200 3,900
2L Therapy 2 9,300 1,300
3L+ Therapy 2 6,100 800
*Other 2 (All these patients are between lines of therapy; 1/3 received maintenance, 2/3 were not on therapy in observation period)
25,300 3,300
1 2013DR/DecisionResources,LLC.Allrightsreserved.Reproduction,distribution,transmissionorpublicationisprohibited. Reprintedwithpermission.FortheCLLdiagnosedincidencetheUSNationalCancerInstituteestimationswereused.2 IMSpatientclaimsestimatesforJuly2012June2013.Note:ThisinformationisanestimatederivedfromtheuseofinformationunderlicensefromthefollowingIMSHealthIncorporatedinformationservice:IMSOncologyTrackingReportsfortheperiodJuly2012toJune2013.IMSexpresslyreservesallrights,includingrightsofcopying,distributionandrepublication.Pharmacyclics,Inc.makesnorepresentationwithrespecttotheaccuracyorreliabilityofthisinformation. Investorsareadvisedtoindependentlyverifythisinformationbeforeusingittomakeinvestmentdecisions.
16
Breakthrough Therapy Designations and Regulatory Progress
IMBRUVICATM approved on November 13, 2013 for the treatment of patients with MCL who have received at least one prior therapy and on February 12, 2014 for the treatment of patients with CLL, who have received at least one prior therapy.
New Drug Application (NDA) submitted in relapsed/refractory MCLand relapsed/refractory CLL on July 10, 2013. NDA was accepted on August 27, 2013 - Priority Review was granted with a PDUFA of Feb 28, 2014.
FDA approved Breakthrough Designations for IMBRUVICA in:o Relapsed/Refractory Mantle Cell Lymphoma (MCL) Feb 2013o Waldenstroms Macroglobulinemia (WM) Feb 2013o Chronic Lymphocytic Leukemia (CLL) with deletion 17p Mar 2013
17
Clinical Development Plan: Select Studies of IMBRUVICA in CLL/SLL PatientsPCYC/JNJ/ISTs Phase Study ID Status
Line ofTherapy
#ofPatients
Trial 1stReleased StudyDesign
CLL
I PCYC1108 compl RR 33 Feb11 i+FCR; i+BR
II
PCYC1103 active RR 200 Jun10 RollOver Study
PCYC1117RESONATE17 active RR 111 Jan13 Monotherapy in17p
PCYC1102 compl TN/RR 133 May10 Monotherapy
BurgerMDACC active RR 40 Feb12 i+R inhighriskpts
BurgerMDACC recruit RR 208 Dec13 ivs iR
III
PCYC1112RESONATE active RR 350 Jun12
i vsOfa(Crossoveradded8/13/13)
PCYC1115RESONATE2 active TN 272 Jan13 i vsChlorambucil inElderly
HELIOS recruit RR 580 Sept12 i+BR
CLL3002 notyet RR 150 Oct13 i vs R(in China)
Woyach notyet TN 523 Jun13 ivsiR vsBRinElderly
CLL12 notyet TN 302 ASH13 ivsPlacebo;Watch&Wait(GermanStudyGroup)
ECOG notyet TN 519 ASH13 iR vs.FCR;YoungFit
18
The Brutons Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients in an Open-Label Extension Study (OBrien, ASH 2013)
A total of 148 patients TN or R/R CLL/SLL received ibrutinibmonotherapy in a phase 1 multiple ascending dose study (PCYC-04753)3 or phase 1b/2 continuous-dosing study (PCYC-1102),4 and were continued on a long-term extension study for follow-up for safety and efficacy with ibrutinibmonotherapy
Median Duration of Response (DOR) was not reached for either Treatment Nave (TN) or Relapsed/Refractory (R/R) responders achieving partial response or better, after a median follow-up of 28.1 and 23.9 months.
At 30 mos, 95.8% of TN and 69.7% of R/R responders were alive without disease progression.
19
The Brutons Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients in an Open-Label Extension Study (OBrien, ASH 2013) The percentage of patients with
a serious Adverse Events grade 3 declined from 43% within the first year of study treatment to 32% after the 1st year of treatment.
Grade 3 AEs (severe) and serious AEs (life threatening) declined from 24% to 7% and serious AEs declined from 8 % to 0% from the first year of treatment to after the first year of treatment.
AEs leading to ibrutinib discontinuation occurred in 8.1% (12/148) of patients within the first year of treatment and declined to 5.5% (6/109) of patients after the first year of treatment.
ResponseRate
n(%)
TN65years(n=31)
R/R(n=117)
Total(N=148)
ORR 25(80.6%) 98(83.8%) 123(83.1%)
ORR+PRL27(87.1%) 104(88.9%) 131(88.5%)
Safety: Treatment-Emergent Related AEs Grade 3 With Incidence 2%
Efficacy: Best Overall Response (ORR)
(PartialResponsewithLymphocytosis)
AEs Grade3=SevereGrade4=LifeThreatening
20
Single Agent Ibrutinib Achieves Equal Responses in CLL Patients With and Without Deletion 17p (Farooqui, ASH 2013)
Patient Population: 53 Total Patients Normal (NL) 17p = 24 pts (8 pts TN/16 pts R/R) Del 17p = 29 pts (15 pts TN/14 pts R/R)
Evaluable at 6 Mo: 47 pts (only 1 PD) Est. Event Free Survival at 14 mo is 93% 4 pts (20%) had no evidence of 17p after 6 mos Del17p does not confer resistance to ibrutinib
Non-Heme Toxicity
Responses Progression Free Survival
(MedianFollowup:14mos)
21
Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk CLL: new, updated results of a Phase II trial in 40 patients (Burger, ASH 2013)
21
i+R resulted in a ORR of 95% in high risk pts. 78% of patients were progression free after 18 mos.
The ORR in the 20 pts with del17p or TP53 mutation was 90% (16 PR, 2 CR).
Questionnaires revealed significantly improved overall health and quality of life after 6 months, which coincided with a significant weight gain at 3 and 6 months.
Treatment generally was well tolerated, with infectious complications (6 cases of pneumonia and 3 cases of upper respiratory infections) being the most common complication. There were two Grade 3, possibly related AEs: mucositis (n=1), and peripheral neuropathy (n=1). Milder toxicities included Grade 1-2 bruising (n=7), Grade 1 subdural hematoma (n=1), fatigue (n=2), bone pain, myalgias, and arthralgia (n=5), or diarrhea (n=1).
22
31 treatment nave pts treated with ibrutinibmonotherapy.
After median follow-up of 22.1 mos, ORR was 71% (13% CR)
Est. PFS: 96.3% at 24 mos (Figure A)
Est. Overall Survival: 96.6% at 24 mos(Figure B)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma:anopen-label, multicentre, phase 1b/2 trial (OBrien, Lancet 2013)
23
Toxicity was mainly of mild-to-moderate severity (grade 12). Three (10%) patients developed grade 3 infections, although no grade 4 or 5 infections
occurred. One patient developed grade 3 neutropenia, and one developed grade 4 thrombocytopenia.
Improvements in hemoglobin, platelet counts, and absolute neutrophil counts were observed in patients treated with ibrutinib
Median serum IgA, IgM, and IgG levels also showed significant improvement.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma:anopen-label, multicentre, phase 1b/2 trial (OBrien, Lancet 2013)
24
Clinical Development Plan: Select Studies of IMBRUVICA in MCL patients
PCYC/JNJ/ISTs Phase Study ID Status
Line ofTherapy
#ofPatients
Trial 1stReleased StudyDesign
MCL
II
PCYC1104 active RR 115 Feb11 Monotherapy
SPARK active RR 120 Aug12 Monotherapy;FailedBR
WangMDACC recruit RR 50 Jul13 i+R
IIIRAY recruit RR 280 Dec12 Monotherapy vs.Temsirol
SHINE recruit TN 520 May13 i+BR inelderly
IV MCL4001 recruit RR 250 Apr13 Monotherapy
25
Highlights EHA 2013: Phase II Monotherapy Trial in Relapsed/Refractory MCL Patients-Long Term Follow Up (Rule, EHA 2013)
PATIENTCHARACTERISTICSFORALLTREATEDPOPULATIONBortezomibNave
(N=63)BortezomibExposed
(N=48)Total
(N=111)
MedianAge, yrs(Range) 66(4683) 69(4084) 68(4084)
Gender:Male 46(73%) 39(81%) 85(77%)
ECOGStatus:0 12>2
53(84%)9(14%)1(2%)
46(96%)2(4%)0(0%)
99(89%)11(10%)1(1%)
Prior Regimens:Median(Range)3regimens
2(15)31(49%)
3(15)30(63%)
3(15)61(55%)
MedianMonthsSinceDiagnosis(Range) 29(3213) 48(7223) 42(3223)
26
HematologicalAE
Bleedingeventsgrade3occurredin5%ofpatients
NonHematologicalAE
.
0% 10% 20% 30% 40% 50% 60%
NeutropeniaThrombocytopenia
Anemia
0% 10% 20% 30% 40% 50% 60%
DiarrheaFatigueNausea
Oedema peripheralDyspnea
ConstipationUpperrespiratorytractinfection
VomitingDecreasedappetite
CoughPyrexia
AbdominalpainContusion
Rash
Grade1Grade2Grade3Grade4Grade5
Highlights EHA 2013: Treatment Related and Unrelated AEs Occurring in >15% of MCL Patients (Rule, EHA 2013)
27
Highlights EHA 2013: Phase II Monotherapy Trial in Relapsed/Refractory MCL PFS and Duration of Response (Rule, EHA 2013)
100
0
80
20
40
60
240 4 128 16 20
P
r
o
g
r
e
s
s
i
o
n
F
r
e
e
S
u
r
v
i
v
a
l
,
%
MonthsFromFirstDose
AllBortezomibExposedBortezomibNaveCensored
111 81 57 33 22 048 37 29 14 10 063 44 28 19 12 0
220
100
0
80
20
40
60
200 4 128 16MonthsFromFirstResponse
75 56 40 24 6 032 26 17 9 3 043 30 23 15 3 0
AllBortezomibExposedBortezomibNaveCensored
P
a
t
i
e
n
t
s
A
l
i
v
e
W
i
t
h
o
u
t
P
r
o
g
r
e
s
s
i
o
n
,
%
Est.medianPFS=13.9mos
Est.medianDOR=17.5mos
28
BestResponse
19 23 21
49 44 47
0
20
40
60
80
100
BortezomibNave(n=63)
BortezomibExposed(n=48)
Total(n=111)
68 67 68
EfficacyPopulationn=111,EstimatedMedianFollowup15.3months
CRPR
P
a
t
i
e
n
t
s
,
%
48.753.2 50.5
47.8 46.0 47.3
0
20
40
60
80
100
2 4 6 9 12 15
R
e
s
p
o
n
s
e
R
a
t
e
,
%
Time,months
66.7 68
52.362.2 64
64.9
ImprovementofCompleteandOverallResponseRatesOverTime
Highlights EHA 2013: Phase II Monotherapy Trial in Relapsed/Refractory MCL Patients-Long Term Follow Up (Rule, EHA 2013)
3.6 9.013.5 17.1
20.7 20.7
29
Clinical Development Plan: Select Studies of IMBRUVICA in DLBCL patients
PCYC/JNJ Phase Study ID Status Line ofTherapy#of
PatientsTrial 1stReleased StudyDesign
DLBCLII
DLB1002 active TN 32 Jun12 i+RCHOP;DLBCL,MCL,FL
PCYC1106 recruit RR 125 May11 Monotherapy
PCYC1123 Notyet RR 110 ASH13 i+R+Len vs.i+Len
PCYC1124 Notyet RR 56 ASH13 i+Len+DAEPOCHR
III DBL3001 recruit TN 800 Sept13 i+RCHOP vs. RCHOP
30
Highlights EHA 2013: Phase II Monotherapy Trial in Relapsed/Refractory DLBCL Patients(Vos, EHA 2013)
Background: Sub-typed for activated B-cell
(ABC) or Germinal Center B(GCB)
Median of 3 prior therapies (1-7)
Results: ABC ORR 41%, CR 17%.
Additional Ongoing Studies: Phase Ib dose escalation with CHOP-R (ORR 100%) Randomized Phase III Frontline CHOP-R+/-
IMBRUVICA in non- GCB (800 patients)
MolecularSubtypePredictsOutcomewithRCHOP
31
Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Treatment-Nave Patients With CD20-Positive B-cell Non-Hodgkins Lymphoma (NHL) (Younes, ASH 2013)
Study Results: 560 mg + R-CHOP resulted in high responses in both GCB and non-GCB pts A Phase 3 trial of R-CHOP ibrutinib is ongoing in de novo non-GCB pts.
32
Clinical Development Plan: Select Studies of IMBRUVICA in Other NHL patients
PCYC/JNJ/ISTs Phase Study ID Status
Line ofTherapy
#ofPatients
Trial 1stReleased StudyDesign
NHL
I
UjjaniNCI recruit TN 33 Apr13 i+R+Len;FL
BlumOSU recruit RR 48 Dec11 i+BR;MZL,FL,WM,DLBCL,MCL
ChristianOSU recruit RR 34 Oct13
i+Len;MZL,FL,WM,DLBCL,MCL
II
PCYC1125 Notyet TN 80 Dec13 i+R;FL
PCYC1121 Notyet RR 60 Oct13 Monotherapy;MZL
FLR2002 recruit RR 110 Apr13 Monotherapy;FL
BartlettNCI recruit RR 40 Apr13 Monotherapy;FL
III FLR3001 Notyet RR 400 Oct13 i+BR ori+RCHOP;FL,MZL
33
Highlights ASH 2012: Phase I Monotherapy Trial Subset of Relapsed/Refractory Follicular Lymphoma Patients (Fowler, ASH 2012)
Background: Prior chemoimmunotherapy Median of 3 prior therapies (1-5)
Results: 16 subjects enrolled: ORR=44% Trend for dose response
o 9 patients >5.0 mg/kg with ORR: 56% (3 CRs and 2 PRs) and median estimated Progression Free Survival = 19.6 months
Study initiated by Janssen: Single arm monotherapy IMBRUVICA Phase II trial in relapsed / refractory
follicular patients Primary endpoint Overall Response Rate
34
Background: Phase I trial, PCYC 04753, PR in 3 out of 4 WM patients Phase II collaboration with the Dana-Farber Cancer Institute
Phase II trial: Safety and efficacy of IMBRUVICA monotherapy in relapsed or refractory
WM patients (2 median priors) 420 mg q day until PD; 30 planned patients Trial expanded from 35 patients to 63 patients.
Updates: Breakthrough Therapy Designation February 2013 PCYC to discuss further development with the FDA
Clinical Development Plan: IMBRUVICA in Waldenstrom patients
IST Phase Study ID Status Line ofTherapy#of
PatientsTrial 1stReleased StudyDesign
WM II TreonDFCI active RR 60 May12 Monotherapy
35
Phase II Monotherapy Investigator sponsored Trial in Relapsed/Refractory Waldenstroms MacroglobulinemiaPatients (Treon, ASH 2013)
IgM andHemoglobinlevelsimprovedpostibrutinib treatment
36
Phase II Monotherapy Investigator sponsored Trial in Relapsed/Refractory Waldenstroms MacroglobulinemiaPatients (Treon, ASH 2013)
Efficacy Response:
83% ORR after a median of 9 cycles
Safety Response:
87.3% (55) patients continued on therapy after a median of 9 cycles
Serious AEs (Grade 3) EventsThrombocytopenia: 7Neutropenia: 9Anemia: 1Pneumonic Infection: 1
37
Highlights ASH 2012: Phase II Monotherapy Trial in Relapsed/Refractory MM Patients (Vij, ASH 2012)
Background: Median of 4 prior treatments Prior bortezomib and lenalidomide
Results: Signals of biologic and clinical activity 5/13 patients had a reduction in paraprotein , 1 PR in combo with dexamethasone Decreases in biomarkers of bone metabolism, angiogenesis and chemotaxis were
observedOngoing Study:
Cohorts 1 (Monotherapy, 420mg) and 2 (560 mg with dex) did not achieve desired results, expansion of these cohorts is not planned.
Expansion to explore IMBRUVICA administration to a 840 mg monotherapy dose and a 840 mg dose in combination with dexamethasone (Cohorts 3&4) is continuing.
Clinical Development Plan: Select Studies ofIMBRUVICA in Multiple Myeloma patients
PCYC/JNJ Phase Study ID Status Line ofTherapy#of
PatientsTrial 1stReleased StudyDesign
MMI PCYC1119 Notyet RR 176 Dec13 i+Carfilzomib
II PCYC1111 recruit RR 164 Mar12 Monotherapy ori+Dex
38
Histone Deacetylase Inhibitor: Abexinostat
Abexinostat is optimized for half-life, oral bioavailability, and potency and synergizes with DNA-damaging agents
Partnered ex-US with Servier, in Phase I/II program in Europe
Phase 2 PCYC study in lymphoma completed and presented at ASH 2012, further updates presented at ICML in Lugano, June 2013
Combination therapies between HDAC and IMBRUVICA are being investigated.
39
Factor VIIa Inhibitor: PCI-27483
First small-molecule FVII-specific inhibitor targeting the tissue factor (TF) pathway
Tissue factor is upregulated in certain tumors. TF:VIIa complex induce signaling pathways that lead to increase in cancer cell migration and invasion
Phase II pancreatic cancer trial completed, results provided at ASCO, June 2013
Further usage of PCI-27483 are currently being investigated
40
Worldwide collaboration to broaden and accelerate the development of IMBRUVICA in oncology, signed in December 2011
$150M upfront; milestones $250M for continued development progress (of which $200M were earned as of May 1, 2013), $225M for regulatory progress and $350M for approval.
Global development plan defined, each company leading the development for specific indications. Development costs shared 40% Pharmacyclics and 60% Janssen for multiple phase III trials
50/50 profit split. Pharmacyclics will book sales and lead commercialization strategy in the US; Janssen will be responsible for the same outside the US
Development and commercialization activities managed through a shared governance structure
Collaboration with Janssen Biotech to Develop and Commercialize IMBRUVICA
41
BROAD PATENT COVERAGE:Our lead product candidates have issued US and European composition of matter patents and are covered by various issued/pending patent applications in other major markets
BTK Inhibitor, IMBRUVICA (ibrutinib - PCI-32765) covered by issued/pending patents projected until 2026* (composition of matter; genus around composition of matter; method of treatment; method of manufacture; inhibition of Btk via specific, irreversible inhibitor)
Factor VIIa Inhibitor, PCI-27483 covered by issued/pending patents projected until 2023*
HDAC Inhibitor, PCI-24781 covered by issued/pending patents projected until 2025*
Strong Patent Portfolio
* which does not include projected patent term extensions in the US
42
Key Corporate Data
GENERAL Current
- Founded- Location- Employees as of 12/31/2013
1991Sunnyvale, CA
484
SELECT FINANCIAL INFORMATION
- Revenue Q4/2013 as of 12/31/2013 $123.6 M
- Non-GAAP Op. Ex Q4/2013 as of 12/31/2013 $28.5 M*
- Cash & Cash Equivalents as of 12/31/2013 $635.6 M**
- Basic Shares Outstanding as of 12/31/2013 74.2 M
Janssen Biotech, Inc. contractual milestones remaining:Development Progress $ 50 million Regulatory Progress $ 100 millionApproval $ 230 million
$ 380 million (earned as of 02/27: upfront $150M, $200M in development milestones, $125M in Regulatory Progress, $120M Approval)
* Non GAAP Expenses do not include $9.6M in stock-based compensation expense and also $50.2M in Excess Amounts paid by Janssen.** Cash does not include $52.0M due to Company by Janssen under the collaboration agreement.
43
PharmacyclicsMakingadifferenceforthe
bettermentofpatients
Slide Number 1Safe Harbor StatementMaking a difference for the betterment of patientsPCYC Corporate Development Jan 2006 to Dec 2008PCYC Corporate DevelopmentJan 2009 to Mar 2014IMBRUVICA Approved November 13, 2013 in MCL and February 12, 2014 in CLLHeadlines and Highlights.Approval Grabs Attention of Top Tier MediaIMBRUVICA (ibrutinib)Leads Our Oncology PipelineIMBRUVICA (Ibrutinib - PCI-32765) BTK Signaling PathwayMechanism of BTK: IMBRUVICA (ibrutinib PCI-32765) Blocks Malignant B-cell Growth and ProliferationSlide Number 12Slide Number 13Patient Populations in Major Hematology MalignanciesCLL/SLL & MCL US Patient Estimates Breakthrough Therapy Designations and Regulatory ProgressClinical Development Plan: Select Studies of IMBRUVICA in CLL/SLL PatientsThe Brutons Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients in an Open-Label Extension Study (OBrien, ASH 2013) The Brutons Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients in an Open-Label Extension Study (OBrien, ASH 2013) Single Agent Ibrutinib Achieves Equal Responses in CLL Patients With and Without Deletion 17p (Farooqui, ASH 2013) Slide Number 21Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma:an open-label, multicentre, phase 1b/2 trial (OBrien, Lancet 2013) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma:an open-label, multicentre, phase 1b/2 trial (OBrien, Lancet 2013) Slide Number 24Highlights EHA 2013: Phase II Monotherapy Trial in Relapsed/Refractory MCL Patients-Long Term Follow Up (Rule, EHA 2013) Slide Number 26Highlights EHA 2013: Phase II Monotherapy Trial in Relapsed/Refractory MCL PFS and Duration of Response (Rule, EHA 2013) Best ResponseClinical Development Plan: Select Studies of IMBRUVICA in DLBCL patientsHighlights EHA 2013: Phase II Monotherapy Trial in Relapsed/Refractory DLBCL Patients(Vos, EHA 2013) Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Treatment-Nave Patients With CD20-Positive B-cell Non-Hodgkins Lymphoma (NHL) (Younes, ASH 2013) Clinical Development Plan: Select Studies of IMBRUVICA in Other NHL patientsHighlights ASH 2012: Phase I Monotherapy Trial Subset of Relapsed/Refractory Follicular Lymphoma Patients (Fowler, ASH 2012) Slide Number 34Phase II Monotherapy Investigator sponsored Trial in Relapsed/Refractory Waldenstroms Macroglobulinemia Patients (Treon, ASH 2013)Phase II Monotherapy Investigator sponsored Trial in Relapsed/Refractory Waldenstroms Macroglobulinemia Patients (Treon, ASH 2013)Highlights ASH 2012: Phase II Monotherapy Trial in Relapsed/Refractory MM Patients (Vij, ASH 2012) Histone Deacetylase Inhibitor: AbexinostatFactor VIIa Inhibitor: PCI-27483 Slide Number 40Strong Patent PortfolioKey Corporate DataSlide Number 43
